The identification of mTOR hyperactivation as key to lymphangioleiomyomatosis pathogenesis has enabled the development of Sirolimus, an oral mTOR inhibitor, as an effective treatment [1]. The gene discussed is MTOR; the disease is lymphangioleiomyomatosis.